European Allergen Manufacturers Group

Hay fever and asthma involve about 25% of the population in industrialised countries.

The optimal preventive treatment is based on induced tolerance by repeated administration of products from the sources of the allergy such as pollen, house dust mites and pets. This treatment - allergen specific Immunotherapy - involves allergen vaccines, also called allergen extracts.

The objective of EAMG is to ensure a favorable environment for optimal use of allergen extracts in the interest of the allergy specialist and the patients.

The XXVIII Congress of the European Academy of Allergy and Clinical Immunology will be held at the Palace of Culture and Science in Warsaw from June 6 to10 2009. Members of EAMG support the educational activities during this meeting with several symposia focusing on the potential of and benefits from allergen specific immunotherapy. New products and concepts including the latest technology in allergen administration and structure will be discussed.

lays down the quality recommendations for allergen products of used for specific immunotherapy (SIT) or in vivo diagnosis of immunoglobulin E (IgE) - mediated allergic diseases. These guidelines addresses issues of study design, efficacy and safety for allergen products being developed for specific immunotherapy of allergic diseases.

The World Allergy Organisation (WAO) that represents more than 70 national scientific allergy societies hosts the XXI World Allergy Congress in Buenos Aires 6-10 December 2009. On the first day of the congress, WAO, the American Academy of Allergy Asthma and Clinical Immunology and the European Academy of Allergy and Clinical Immunology have arranged a full day symposium dedicated to allergen specific immunotherapy – the “2nd immunotherapy day”.

Allergen Specific Immunotherapy (SIT) is the only treatment that influences the basic course of the allergic diseases (WHO Position Paper 1998) and is so far the only treatment for respiratory allergic diseases which has shown the capacity to prevent development of asthma (WHO Allergic Rhinitis and its impact on Asthma report 2007 – update).